Valeant pays $11bn in cash for GI specialist Salix
Executive Summary
Valeant Pharmaceuticals International Inc. offered to pay $10bn--$158.00 in cash per share (a 7% premium)--for public gastrointestinal-focused specialty pharmaco Salix Pharmaceuticals Ltd.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice